What Is Overall Survival (OS) in Cancer, and Why Does It Matter?

📰 Recent Development: The FDA Reprioritizes “Overall Survival”

In October 2025, The Lancet Oncologypublished a commentary (Stevens SX, Teuwen LA, Gyawali B. Overall survival assessment in cancer drug trials: a luxury or a necessity?) sharing a noteworthy development. It quoted the new guidance issued by the US Food and Drug Administration (FDA) in August 2025:

“Overall survival should be prioritized as the primary endpoint when feasible.” — FDA Draft Guidance, August 2025

The FDA is therefore now clearly saying: “Overall survival is the most reliable clinical endpoint for confirming a cancer drug’s benefit.” This emphasis represents a significant shift regarding drugs approved in recent years solely on intermediate endpoints, such as tumor shrinkage or PFS.

One of the article’s authors, Dr. Bishal Gyawali, describes this shift as “a reminder that the true goal of cancer treatment is not merely to prolong life, but to improve it meaningfully.”

Why Is It So Important?

Cancer treatment aims to improve both length and quality of life, rather than simply shrink tumors. Thus, “Overall Survival (OS)”is considered oncology’s “gold-standard endpoint” . Simply put, OS is the time from when a patient starts treatment until death occurs.

Because it encompasses all lines of treatment, supportive care and the disease’s biological behavior, this measure most accurately reflects a treatment’s real-world impact on survival.

How Is Overall Survival Measured?

• Defined starting point: Usually randomization (entry into the trial) or the date treatment starts.
• Endpoint: The date of death from any cause, whether cancer or another cause.
• Median OS: The time by which half of the study patients have died. For example, “Median OS: 24 months” means that 50% of patients died within 24 months and 50% lived longer.

This time is generally visualized using Kaplan–Meier curves , and between-group differences are expressed statistically with the Log-rank test or hazard ratio (HR) measures.

The Difference Between Overall Survival (OS) and Progression-Free Survival (PFS)

Clinical trials often assess both OS and PFS (Progression-Free Survival) . PFS measures the time until tumor growth or new metastases develop, while OS focuses on the patient’s lifespan.

For example, if a new treatment in a trial increases PFS from 8 to 12 months but produces no OS difference, it means that treatment slows disease progression without extending life for the patient.

The Role of OS in Clinical Trials

Regulators such as the FDA and EMA regard an increase in OSas the strongest evidence for oncology drug approval. In some cases, however, particularly with immunotherapy or targeted agents, the OS difference may emerge late.

• Immunotherapies: May produce a long-term “survival tail” even without an initial difference (for example, curves separate after 3 years).
• Targeted therapies: PFS gains appear early, but developing resistance may erase the OS difference.
• Combination therapies: May provide both early and long-term gains (for example, the KEYNOTE-B96 trial).

Looking Ahead: How Can We Predict OS Earlier?

In modern oncology, rather than waiting for OS data, we now try to predict this outcome using early biomarkers . For example:

• ctDNA clearance: Disappearance of minimal residual disease may be an early indicator of improved OS.
• T-cell activation signatures: The strength of the immune response may predict long-term survival.
• Real-world data (RWD): Represent broader populations, complementing OS results from clinical trials.

In the future, OS will become a multidimensional measure answering not only “How many months did the patient live?” but also “How did they live, how did they respond and who benefited most?”